These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

498 related articles for article (PubMed ID: 21145399)

  • 1. Experimental approaches to the interaction of the prion protein with nucleic acids and glycosaminoglycans: Modulators of the pathogenic conversion.
    Silva JL; Vieira TC; Gomes MP; Rangel LP; Scapin SM; Cordeiro Y
    Methods; 2011 Mar; 53(3):306-17. PubMed ID: 21145399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intriguing nucleic-acid-binding features of mammalian prion protein.
    Silva JL; Lima LM; Foguel D; Cordeiro Y
    Trends Biochem Sci; 2008 Mar; 33(3):132-40. PubMed ID: 18243708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prion protein self-interactions: a gateway to novel therapeutic strategies?
    Rigter A; Langeveld JP; van Zijderveld FG; Bossers A
    Vaccine; 2010 Nov; 28(49):7810-23. PubMed ID: 20932496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nucleic acid and prion protein interaction produces spherical amyloids which can function in vivo as coats of spongiform encephalopathy agent.
    Nandi PK; Nicole JC
    J Mol Biol; 2004 Nov; 344(3):827-37. PubMed ID: 15533448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of RNA in mammalian prion protein conversion.
    Gomes MP; Vieira TC; Cordeiro Y; Silva JL
    Wiley Interdiscip Rev RNA; 2012; 3(3):415-28. PubMed ID: 22095764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conformational conversion of prion protein in prion diseases.
    Zhou Z; Xiao G
    Acta Biochim Biophys Sin (Shanghai); 2013 Jun; 45(6):465-76. PubMed ID: 23580591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural insights into the interaction between prion protein and nucleic acid.
    Lima LM; Cordeiro Y; Tinoco LW; Marques AF; Oliveira CL; Sampath S; Kodali R; Choi G; Foguel D; Torriani I; Caughey B; Silva JL
    Biochemistry; 2006 Aug; 45(30):9180-7. PubMed ID: 16866364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of genuine prion infectivity by serial PMCA.
    Weber P; Giese A; Piening N; Mitteregger G; Thomzig A; Beekes M; Kretzschmar HA
    Vet Microbiol; 2007 Aug; 123(4):346-57. PubMed ID: 17493773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNA molecules stimulate prion protein conversion.
    Deleault NR; Lucassen RW; Supattapone S
    Nature; 2003 Oct; 425(6959):717-20. PubMed ID: 14562104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prions and transmissible spongiform encephalopathy (TSE) chemotherapeutics: A common mechanism for anti-TSE compounds?
    Caughey B; Caughey WS; Kocisko DA; Lee KS; Silveira JR; Morrey JD
    Acc Chem Res; 2006 Sep; 39(9):646-53. PubMed ID: 16981681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Biology of non-conventional transmissible agents or prions].
    Dormont D
    Rev Neurol (Paris); 1998 Feb; 154(2):142-51. PubMed ID: 9773035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prions at the crossroads: the need to identify the active TSE agent.
    Nandi PK
    Bioessays; 2004 May; 26(5):469-73. PubMed ID: 15112226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The highways and byways of prion protein trafficking.
    Campana V; Sarnataro D; Zurzolo C
    Trends Cell Biol; 2005 Feb; 15(2):102-11. PubMed ID: 15695097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prion protein oligomer and its neurotoxicity.
    Huang P; Lian F; Wen Y; Guo C; Lin D
    Acta Biochim Biophys Sin (Shanghai); 2013 Jun; 45(6):442-51. PubMed ID: 23557632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strain-specific effects of reducing agents on the cell-free conversion of recombinant prion protein into a protease-resistant form.
    Imamura M; Kato N; Okada H; Iwamaru Y; Shimizu Y; Mohri S; Yokoyama T
    Microbiol Immunol; 2011 Sep; 55(9):633-40. PubMed ID: 21645053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experimental approaches to TSE prevention via inhibition of prion formation.
    Politopoulou G
    Protein Pept Lett; 2004 Jun; 11(3):249-55. PubMed ID: 15182226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unraveling the details of prion (con)formation(s): recent advances by mass spectrometry.
    Principe S; Maras B; Schininà ME; Pocchiari M; Cardone F
    Curr Opin Drug Discov Devel; 2008 Sep; 11(5):697-707. PubMed ID: 18729021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 25 nm virion is the likely cause of transmissible spongiform encephalopathies.
    Manuelidis L
    J Cell Biochem; 2007 Mar; 100(4):897-915. PubMed ID: 17044041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prion protein has DNA strand transfer properties similar to retroviral nucleocapsid protein.
    Gabus C; Auxilien S; Péchoux C; Dormont D; Swietnicki W; Morillas M; Surewicz W; Nandi P; Darlix JL
    J Mol Biol; 2001 Apr; 307(4):1011-21. PubMed ID: 11286552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prion protein interconversions.
    Caughey B
    Philos Trans R Soc Lond B Biol Sci; 2001 Feb; 356(1406):197-200; discussion 200-2. PubMed ID: 11260800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.